Last reviewed · How we verify
GSK2798745 solution
GSK2798745 solution is a glucagon-like peptide-1 (GLP-1) receptor agonist.
GSK2798745 solution is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.
At a glance
| Generic name | GSK2798745 solution |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
It works by mimicking the action of the natural hormone GLP-1, which helps to regulate blood sugar levels. This leads to increased insulin secretion and decreased glucagon secretion, resulting in improved glycemic control.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2798745 solution CI brief — competitive landscape report
- GSK2798745 solution updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI